Literature DB >> 2173781

Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

F Delpeyroux1, E Van Wezel, B Blondel, R Crainic.   

Abstract

We have studied the functional expression of antigenic poliovirus fragments carried by various hybrid hepatitis B surface antigen (HBsAg) particles. Several constructions were made by using two different insertion sites in the HBsAg molecule (amino acid positions 50 and 113) and two different sequences, one derived from poliovirus type 1 (PV-1) and the other from PV-2. The inserted fragments each encompassed residues 93 to 103 of the capsid protein VP1, a segment which includes the linear part of the neutralization antigenic site 1 of the poliovirus. The antigenicity and immunogenicity of the hybrid particles were evaluated and compared in terms of poliovirus neutralization. A high level of antigenic and immunogenic activity of the PV-1 fragment was obtained by insertion at position 113 but not at position 50 of HBsAg. However, a cooperative effect was observed when two PV-1 fragments were inserted at both positions of the same HBsAg molecule. Antibodies elicited by the PV-2 fragment inserted at amino acid position 113 did not bind or neutralize the corresponding poliovirus strain. They did, however, bind a chimeric poliovirus in which the homologous antigenic fragment of PV-1 had been replaced by that of PV-2. The only virions that were neutralized by these antibodies were certain mutants carrying amino acid substitutions within the PV-2 fragment. These results show that position, constraints from the carrier protein, and nature of the inserted sequences are critically important in favoring or limiting the expression of antigenic fragments as viral neutralization immunogens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173781      PMCID: PMC248783          DOI: 10.1128/JVI.64.12.6090-6100.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

2.  Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.

Authors:  M Ferguson; D M Evans; D I Magrath; P D Minor; J W Almond; G C Schild
Journal:  Virology       Date:  1985-06       Impact factor: 3.616

3.  Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody.

Authors:  F G Uytdehaag; A D Osterhaus
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

4.  Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides.

Authors:  S E Brown; C R Howard; A J Zuckerman; M W Steward
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

5.  Efficient isolation of genes by using antibody probes.

Authors:  R A Young; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

6.  A new dominant hybrid selective marker for higher eukaryotic cells.

Authors:  F Colbère-Garapin; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  J Mol Biol       Date:  1981-07-25       Impact factor: 5.469

7.  Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  Nature       Date:  1983 Aug 25-31       Impact factor: 49.962

8.  Natural variation of poliovirus neutralization epitopes.

Authors:  R Crainic; P Couillin; B Blondel; N Cabau; A Boué; F Horodniceanu
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

Review 9.  Synthetic peptide immunogens as vaccines.

Authors:  T M Shinnick; J G Sutcliffe; N Green; R A Lerner
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

10.  Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1.

Authors:  S van der Werf; C Wychowski; P Bruneau; B Blondel; R Crainic; F Horodniceanu; M Girard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

View more
  6 in total

1.  Deletions in the hepatitis B virus small envelope protein: effect on assembly and secretion of surface antigen particles.

Authors:  R Prange; R Nagel; R E Streeck
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.

Authors:  H J Netter; T B Macnaughton; W P Woo; R Tindle; E J Gowans
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

5.  Proposition of a three-dimensional representation of the constitutive protein of the hepatitis B surface antigen particles.

Authors:  N Sonveaux; J M Ruysschaert; R Brasseur
Journal:  J Protein Chem       Date:  1995-08

6.  Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein.

Authors:  C M Mangold; R E Streeck
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.